Fc-optimized anti-CCR8 antibodies selectively deplete CCR8-expressing Tregs within tumors without affecting CCR8+ T cells elsewhere, effectively suppressing tumor growth (89, 90). The gene discussed is CCR8; the disease is neoplasm.